Speedier drug approvals hit slowdown as FDA faces scrutiny - New Delhi Times - India Only International Newspaper
Expedited drug approvals slowed this year as the Food and Drug Administration’s controversial accelerated pathway came under new scrutiny from Congress, government watchdogs and some of the agency’s own leaders. With less than a month remaining in the year, the FDA’s drug center has granted 10 accelerated approvals — fewer than the tally in each…